It is already known that PPARγ can suppress tumorigenesis through regulation and interaction with β-catenin (Girnun et al., 2002; Jansson et al., 2005), and that PPARγ agonist inhibits the development of colon cancer (Brockman et al., 1998; Sarraf et al., 1998). This evidence concerns the gene PPARG and malignant colon neoplasm.